Therapeutics Companies Worldwide
Therapeutics companies develop, manufacture, and distribute medical devices, diagnostics, or pharmaceutical products for use in clinical, hospital, and research settings. This page lists companies operating in the Therapeutics sector based on self-reported profile data. The directory currently holds 120 companies in this sector. The largest share of listings is based in United States (US). Related sectors on Enterprise League include Laboratories, Genetics, First Aid, Health and Medical Products, Biopharma, Clinical Trials, Diabetes.
120 companies
United States (US) top country
Location
Category
Therapeutics
List of Therapeutics companies in All locations
120 companies
Sort by
At IV Nutrition Brookfield, we specialize in IV therapy designed to boost your body’s recovery, enhance self-healing, and protect you from illnesses.
Therapeutics
Health and Medical Products
Medical
At Innate Therapies, we invite you to embark on a transformative journey towards holistic well-being. Our sanctuary of healing offers a diverse range of therapeutic services designed to nurture your mind, body, and spirit. From rejuvenating massage therapies to mindfulness practices and energy healing sessions, our dedicated team of experienced practitioners is committed to guiding you on a path to optimal wellness. Our approach is rooted in the belief in the body's innate ability to heal itself, and our personalized treatments are crafted to enhance your natural balance and vitality.
Therapeutics
SOTIO Biotech is shaping the future of cancer immunotherapies by translating compelling science into patient benefit. SOTIO’s robust clinical pipeline includes a differentiated superagonist of the attractive immuno-oncology target IL-15, a proprietary technology designed to improve on the efficacy of CAR T therapies and a new generation of potent and stable antibody-drug conjugates (ADCs). SOTIO is a member of the PPF Group.
Medical
Therapeutics
Biotechnology
Healthcare
PathoQuest helps biopharmaceutical developers and manufacturers get their therapies to market with our leading expertise in GMP NGS-based biosafety testing and characterization services.
As innovator companies continue to bring exciting novel therapies to market, there is a critical need for alternative biosafety and characterization strategies. This is especially the case for life-changing cell and gene therapies, as well as novel viral vaccines. Classical testing approaches, such as cell based assays, are often challenging to implement due to high volume requirements, as well as compatibility issues.
Biosafety testing and characterization are key regulatory requirements for the release of biologic therapies. Therefore, alternative methods which can address these issues are of intense interest. There is also a drive from across industry and regulators to reduce, and eventually eliminate the use of animal models used in biosafety testing.
The genomic approach of Next Generation Sequencing (NGS) can solve many of the challenges that are faced by developers and manufacturers, such as lower volume requirements and incompatibility with cell-based assays
From our origins within the Institut Pasteur, PathoQuest is leading the way in expertise for the provision of GMP NGS based biosafety testing. Our expertise is underlined with over 20 peer reviewed publications on NGS applications in biosafety testing; as well as active participation in industry groups such as PDA, ADVTIG, CAACB and EFPIA. PathoQuest are committed to bringing this game-changing genomic approach to biopharmaceutical developers and manufacturers.
PathoQuest has a global footprint, with operations in Europe (Paris) and North America (Wayne, PA); and have provided NGS biosafety testing services to over 100 of the top biopharmaceutical companies globally.
Why not get in touch to see how we can help you with your biosafety testing strategy?
Therapeutics
Healthcare
Biotechnology
Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.
Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases.
Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks.
The company was founded in 2000 and has offices in Spain and the United States.
Medical
Genetics
Healthcare
Biopharma
Therapeutics
Biotechnology
Ori Biotech is a London- and New Jersey-based leader in CGT manufacturing technology that has developed a proprietary, bespoke and flexible manufacturing platform, which enables patient access to a new generation of personalised, lifesaving treatments.
By fully automating and standardising CGT manufacturing in a closed platform, Ori offers therapeutics developers the opportunity to seamlessly scale from pre-clinical process development to commercial scale manufacturing.
So complex manufacturing challenges can be put where they belong – in the past.
Manufacturing
Industrial Automation
Biotechnology
Therapeutics
Industrial Machinery and Equipment
Ochre Bio is a biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for important liver health challenges, from increasing donor liver supply to reducing cirrhosis complications. To learn more, please visit www.ochre-bio.com.
Biopharma
Therapeutics
Healthcare
Biotechnology
Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat disease. The dark genome holds more than 90% of disease-linked genetic variants whose value remains untapped, representing a significant opportunity for drug discovery and development. The Company has the unique ability to link these variants to gene function and precisely map disease pathways. Nucleome’s cell type-specific platform creates high resolution 3D genome structure maps and enables variant functional validation at scale in primary cell types, enabling the discovery and development of novel, better and safer drugs. The initial focus of the company is on lymphocytes and related autoimmune disease. Nucleome’s ambition is to build a robust pipeline of drug assets, with corresponding biomarkers. Nucleome Therapeutics was founded by leading experts in gene regulation from the University of Oxford. For more information, please visit www.nucleome.com.
Therapeutics
Genetics
Biotechnology
NeoPhore is creating novel small molecule immuno-oncology therapeutics. NeoPhore's drugs target genetic mechanisms that both clinical and lab validation studies suggest will promote neoantigen creation and diversity across numerous cancers. Alone or in combination with other cancer immunotherapies, drugs that spark cancer neoantigen creation are designed to stimulate the immune system and improve outcomes for patients who fail to benefit from the current generation of cancer immunity therapeutics.
Therapeutics
Legal Translation Services
Biotechnology
Mission Therapeutics is a private, drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat diseases of high unmet need.
Mission has built a world-leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging, and hitherto intractable, drug class that is attracting significant commercial interest as the potential ‘Next Kinase Area’.
Mission’s DUB platform is yielding a rich pipeline of novel therapeutics for the benefit of patients across therapeutic areas.
Mission’s strategy is to create value by advancing its pipeline programmes through early clinical development, and preferentially with a patient selection strategy to enhance the probability of demonstrating early signs of efficacy.
Mission’s leadership team has a wealth of international, commercial and scientific experience, and the company has strong links with key academic and research centers including Cancer Research UK Laboratories and the Jackson Laboratories at the Gurdon Institute, University of Cambridge.
The Company has to date received £87 million in venture capital from a blue chip syndicate comprising institutional and corporate investors and was awarded a £1.9 million grant from Innovate UK in September 2015.
In February 2016, the Company raised £60 million in a Series C financing led by Imperial Innovations and new investor Woodford Patient Capital Trust. It included follow-on investment from existing shareholders Sofinnova Partners, SR One, Roche Venture Fund and Pfizer Venture Investments. Mission is based at the Babraham Research Campus, south of Cambridge.
Therapeutics
Life Science
Healthcare
Biotechnology
MindMaze is a global leader in digital neuro-therapeutics (DTx) solutions with a mission to accelerate the brain's ability to recover, learn and adapt. With over a decade of work at the intersection of neuroscience, bio-sensing, engineering, mixed reality and artificial intelligence, its healthcare division is addressing some of the most challenging problems in neurology, including stroke, Alzheimer disease and Parkinson disease, by creating the universal platform for brain health and recovery and unique digital therapeutic interventions. MindMaze's pioneering FDA cleared and CE marked neuro-digital therapeutics accelerate patients' recovery from many critical neurological conditions. Founded in 2012 by CEO Dr Tej Tadi, MindMaze is the first Swiss Unicorn with offices in Lausanne, Baltimore, London, Paris and Mumbai.
Neuroscience
Healthcare
Therapeutics
AR and VR Development
Biotechnology
Mindable Health offers a therapeutic app to overcome anxiety.
Therapeutics
Mental Health Care
Mobile App Development
Healthcare
Microbiotica identifies gut bacteria linked to phenotype with unprecedented precision in order to discover and develop live bacterial therapeutics and biomarkers from clinical datasets.
Initially built out of 10 years investment in the Wellcome Sanger Institute, Microbiotica has unrivalled capabilities in microbiome analysis linked to patient phenotype. It is a global leader in gut bacterial culturing, and has a world leading microbiome Culture Collection, proprietary Reference Genome Database and advanced microbiome bioinformatics. The company also has advanced capabilities in microbiome/host biology and preclinical development of bacterial products.
Microbiotica has a pipeline of highly differentiated clinically-derived products including Live Bacterial Therapeutics and Biomarkers in IBD, Immuno-oncology and Gut Epithelial Barrier Repair.
It has collaborations with Cancer Research UK and Cambridge University Hospitals in Immuno-oncology, Genentech/Roche in IBD, and University of Adelaide in Ulcerative Colitis.
Therapeutics
Healthcare
Biotechnology
Ludocare is to create ways to provide assistance to patients and their families to improve their abilities, autonomy, and quality of life.
Therapeutics
Childcare
Healthcare
Medical Equipment and Services
Kynos Therapeutics is poised to bring a new generation of potent first-in-class KMO inhibitors to the market - ready to impact on unmet medical needs.
Kynos Therapeutics Ltd. is a Private Limited Company Registered in England and Wales, Company number 12501037
Medical
Therapeutics
Healthcare
Biotechnology
Manufacturing
FIRE1 aims to improve patient quality of life, and patient outcomes, while lowering overall healthcare costs.
Health and Medical Products
Medical
Healthcare
Therapeutics
Medical Equipment and Services
Biotechnology
AFYX Therapeutics is a private biopharmaceutical company focused on innovative approaches to treat mucosal diseases.
The Company has developed the Rivelin patch, a breakthrough therapy for the treatment of mucosal diseases. Rivelin is designed to deliver a pharmaceutical drug uni-directionally to a mucosal surface using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.
AFYX's lead Rivelin patch product candidate seeks to treat the auto-immune, inflammatory disease oral lichen planus (OLP) through direct delivery of the drug clobetasol propionate. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients have increased risk of developing mouth cancer in the affected areas. No U.S. Food and Drug Administration (FDA) approved treatment exists, with today’s off-label treatment ranging from topical corticosteroids to laser ablation. It is estimated that OLP affects 1% to 2% of the population.
Following successful results from a Phase 1b clinical study of the non-drug-loaded Rivelin patch in patients with OLP, AFYX has begun a Phase 2b clinical study of the clobetasol-loaded Rivelin patch in the United States and various countries in Europe.
Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.
Shipping and Delivery
Healthcare
Therapeutics
Clinical Trials
Pharmaceutical
Biotechnology
To contact us : contact@calixar.com
CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens.
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
Therapeutics
Pharmaceutical
Biotechnology
Evotec is a life science company with a unique business model focused on delivering highly effective new therapeutics to the patients.
The Company leverages its multimodality platform, the “Data-driven R&D Autobahn to Cures”, for proprietary projects and within a network of partners including Pharma, Biotech, academics, and other healthcare stakeholders.
With more than 4,500 highly qualified people at 17 sites, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics.
Therapeutics
Healthcare
Pharmaceutical
Biotechnology
We are Bicycle Therapeutics, a clinical-stage biopharmaceutical company. We didn’t wait for the next advance against cancer. We created it.
Based on groundbreaking work conceived in the laboratory of Sir Greg Winter with the help of Professor Christian Heinis, we are pioneering the development of bicyclic peptides, or Bicycles® – a novel class of versatile, chemically synthesized medicines. Bicycles are fully synthetic short peptides constrained to form two loops which stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches. Bicycles represent a unique therapeutic class, combining the pharmacological properties normally associated with a biologic with the manufacturing and pharmacokinetic advantages of a small molecule, yet with no signs of immunogenicity observed to date.
Bicycles can be used as Bicycle conjugates to deliver toxin payloads and to precisely target local immune activation within tumors and as Bicycle T-cell modulators, which activate cytotoxic T-cells while circumventing the limitations of antibody and biologic therapies and better enabling combination therapy. Our lead product candidate, BT1718, is a Bicycle toxin conjugate currently being investigated in a Phase I/IIa open label dose escalation and expansion clinical trial sponsored by Cancer Research UK. BT1718 targets Membrane Type 1 Matrix Metalloproteinase (MT1-MMP), also known as MMP-14, which is highly expressed in many solid tumors.
Our strategic collaborations are based on the ability of Bicycles to address a wide variety of targets. Through collaborations with AstraZeneca, Oxurion, Innovate UK and the Dementia Discovery Fund, we work with companies that have deep therapeutic expertise outside of oncology to enable us to more efficiently develop novel medicines for patients.
Medical Equipment and Services
Therapeutics
Health and Medical Products
Biotechnology
Company Name | Location | Category | Employees | Accuracy | Website | |
|---|---|---|---|---|---|---|
Brookfield, United States (US) | Health and Medical Health and Medical | 2-10 | jason@ivnutrition.com | https://ivnutrition.com/locations/milwaukee-brookfield-wi/ | ||
Paramatta Park, Australia | Health and Medical Health and Medical | 30-50 | adminteam@innatetherapies.com | https://innatetherapies.com/ | ||
Prague, Czechia | Health and Medical +1 Health and Medical, Science and Engineering | 150-200 | media@sotio.com | https://sotio.com/ | ||
Paris, France | Health and Medical +1 Health and Medical, Science and Engineering | 50-100 | contact@pathoquest.com | https://www.pathoquest.com/ | ||
Barcelona, Spain | Health and Medical +1 Health and Medical, Science and Engineering | 50-100 | info@oryzon.com | https://www.oryzon.com/en | ||
London, United Kingdom (UK) | Manufacturing and Industry +2 Manufacturing and Industry, Science and Engineering, Health and Medical | 50-100 | info@oribiotech.com | https://oribiotech.com/ | ||
Oxford, United Kingdom (UK) | Health and Medical +1 Health and Medical, Science and Engineering | 50-100 | contact@ochre-bio.com | https://www.ochre-bio.com/ | ||
Oxford, United Kingdom (UK) | Health and Medical +1 Health and Medical, Science and Engineering | 30-50 | info@nucleome.com | https://nucleome.com/ | ||
Cambridge, United Kingdom (UK) | Health and Medical +2 Health and Medical, Legal, Science and Engineering | 10-20 | info@neophore.com | https://www.neophore.com/ | ||
Cambridge, United Kingdom (UK) | Health and Medical +1 Health and Medical, Science and Engineering | 50-100 | info@missiontherapeutics.com | http://missiontherapeutics.com/ | ||
Lausanne, Switzerland | Science and Engineering +2 Science and Engineering, Health and Medical, Information Technology | 150-200 | info@mindmaze.com | https://mindmaze.com/ | ||
Berlin, Germany | Health and Medical +1 Health and Medical, Information Technology | 10-20 | team@mindable.health | https://www.mindable.health/ | ||
Cambridge, United Kingdom (UK) | Health and Medical +1 Health and Medical, Science and Engineering | 50-100 | info@microbiotica.com | https://microbiotica.com/ | ||
Lyon, France | Health and Medical +1 Health and Medical, Public and Community | 10-20 | info@ludocare.com | https://www.ludocare.com/ | ||
Edinburgh, United Kingdom (UK) | Health and Medical +2 Health and Medical, Science and Engineering, Manufacturing and Industry | 2-10 | admin@kynostx.com | http://www.kynostx.com/ | ||
Dublin, Ireland | Health and Medical +1 Health and Medical, Science and Engineering | 100-150 | info@fire1foundry.com | https://fire1foundry.com/ | ||
Copenhagen, Denmark | Professional Services +2 Professional Services, Health and Medical, Science and Engineering | 10-20 | inquiry@afyxtx.cominquiry | https://afyxtx.com/ | ||
Lyon, France | Health and Medical +1 Health and Medical, Science and Engineering | 10-20 | contact@calixar.com | https://www.calixar.com/ | ||
Hamburg, Germany | Health and Medical +1 Health and Medical, Science and Engineering | 5000+ | info@evotec.com | https://www.evotec.com/en | ||
Cambridge, United Kingdom (UK) | Health and Medical +1 Health and Medical, Science and Engineering | 200-500 | info@bicycletherapeutics.com | https://www.bicycletherapeutics.com/ |
50/120 results
Frequently asked questions
FAQ updated November 2025
What is Enterprise League?
Enterprise League is a business platform built for the doers, small businesses and startups who want to get seen, get leads, and grow.We help you showcase your company, connect directly with potential clients and partners, and get valuable insights into your performance, all without the middlemen or the fluff. Whether you're a team of 2 or 200, Enterprise League puts you on equal ground with the big players.
How can my business benefit from joining Enterprise League?
You get visibility, leads, and control, all in one place. Joining Enterprise League puts your business in front of thousands of verified companies. List your services, connect with decision-makers, and see real-time data on who’s visiting your profile.It’s a streamlined way to grow your presence, build partnerships, and stop relying on outdated directories or cold outreach.
What are the key features of Enterprise League?
Enterprise League gives you tools to grow faster: • Custom Profiles:Boost your visibility with a standout business profile. • Smart search: Get found by clients looking for your exact services. • Real analytics: See who's visiting, what's working and where you rank. • Direct messaging: Skip the cold emails and chat direct with prospects. • Reviews insights: Showcase real reviews and let AI highlight what matters. • Zero-fee marketplace: List and find products or services for free.
Can I try Enterprise League for free?
Absolutely. Our Free Plan is built for small businesses. You get profile visibility, marketplace access, and business directory use, free. Want more reach and features? Upgrade when you’re ready. No pressure.
How does the Interactive Business Directory work?
It’s like Google, but only for serious businesses. Search by location, size, or sector. Visit company profiles, send a message, or download insights. It’s built for real B2B decisions, not noise.
How can I download business insights?
Need competitor or market data? We’ve got it, and yes, you can download it. With our Business Insights Download feature, you can export detailed company and industry data in CSV format, including decision-makers, background info, and more. It’s perfect for sales targeting, market research, or just getting smarter about your next move.
How does the Reviews feature work?
Show off your best reviews, without lifting a finger. We pull your reviews from Google, Facebook, Trustpilot and more. Then our AI highlights the most important insights. You just sit back and shine.
What plans are available?
Three simple plans: Free Plan: Get started with a verified profile, search access, and the ability to add products and services. Premium: More reach, more leads, deeper analytics. Ultimate: All the bells and whistles, including a dedicated growth partner.
How can my company win an award?
We highlight the best of the best, and that could be you. We run 50+ startup award categories every year. Apply for free. Winners get recognition, visibility, and bragging rights.